Severe Community-Acquired Pneumonia Caused by Methicillin-Sensitive Staphylococcus aureus: Successfully Treated with Contezolid – A Case Report and Literature Review
Kaifei Wang,Ye Hu,Zhimei Duan,Han Fu,Xingshuo Hu,Ying Zhao,Ruoxuan Wen,Lina Li,Fei Xie
DOI: https://doi.org/10.2147/IDR.S406799
2023-05-24
Infection and Drug Resistance
Abstract:Kaifei Wang, Ye Hu, Zhimei Duan, Han Fu, Xingshuo Hu, Ying Zhao, Ruoxuan Wen, Lina Li, Fei Xie College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing, People's Republic of China Correspondence: Fei Xie, College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, People's Republic of China, Tel +86-15001028681, Email Background: Staphylococcus aureus has been well recognized as an important cause of community-acquired pneumonia (CAP), with non-specific characteristics and poor prognosis. In severe CAP (SCAP) guidelines, β-lactam combined with macrolides or fluoroquinolones therapy was recommended, but the efficacy is not satisfactory due to the continued spread of antimicrobial resistance. Contezolid is a new representative of oxazolidinones in clinical development, but no relevant reports have been reported for the treatment of SCAP. This was the first report of a patient with Staphylococcus aureus SCAP who was successfully treated with contezolid combined with other antibiotics and rehabilitation exercise. Case Presentation: A 44-year-old woman with high blood pressure and diabetes was admitted to our hospital owing to cough, sputum, wheezing for 2 weeks, and aggravation for 2 days. The bronchoscopic alveolar lavage and microorganism-Rapid On Site Evaluation (BAL-mROSE) was used to get pathological data, which were positive for Staphylococcus aureus , in line with blood cultures. During hospitalization, the patient received endotracheal intubation for assisted breathing and anti-infective therapy, including meropenem, linezolid, teicoplanin and tazocin successively. Finally, contezolid obtained excellent result, with platelet recovery to normal levels and significant improvement in pulmonary imaging. Meanwhile, the patient's swallowing disorder improved after continuous rehabilitation exercise. After discharge, she received contezolid consolidation therapy for 1 week and was free of complaints during the 30-day follow-up without any special treatment for SCAP. Discussion: Treatment with contezolid combined with other antibiotics and rehabilitation exercise for SCAP has shown remarkable efficacy and good safety; hence, this regimen is a promising treatment strategy for this fatal disease. Keywords: severe community-acquired pneumonia, methicillin-sensitive Staphylococcus aureus , antibiotic therapy, contezolid, rehabilitation exercise Staphylococcus aureus is one of the most difficult Gram-positive pathogens to treat and is commonly isolated as a cause of serious health care-associated infections, including pneumonia. 1 The classification of pneumonia includes community-acquired pneumonia (CAP), hospital-acquired pneumonia and ventilator-associated pneumonia. 2 Among the typical causes bacterial of CAP, Staphylococcus aureus accounted for less than 5% of all cases and was associated with worse clinical outcomes. 3 In addition, the clinical features of Staphylococcus aureus pneumonia are non-specific, which makes the treatment of infection more complex. 2 In recent decades, the number of patients requiring intensive care management due to severe community-acquired pneumonia (SCAP) has increased worldwide, resulting in a severely high clinical burden. Existing data also positively point out that the delay in admission to the intensive care unit (ICU) significantly increases mortality in patients with SCAP. 4 These findings suggest that it is urgent to timely identify patients who need intensive care management and give guidance to empirical antibiotic treatment. Current guidelines recommend the use of β-lactam alone or combination with a macrolide or fluoroquinolone for the treatment of CAP, except in patients admitted to the ICU, patients with concomitant diseases, or patients with risk factors associated with greater resistance to pathogens causing pneumococcal CAP. 5 In patients admitted to the ICU, β-lactam is recommended in combination with macrolides or fluoroquinolones. 6 However, due to the continued spread of antimicrobial resistance, this has greatly increased incidence rate, mortality and health care costs. Therefore, alternative treatments and novel drugs should be considered. Oxazolidinones are a kind of synthetic antimicrobial agents, which is used to treat serious infections caused by Gram-positive pathogens. They can inhibit the elongation of polypeptide chain during protein synthesis by binding to the A site of bacterial ribosomes. 7 The mechanism of oxazolidinone is unique, and there is no cross-resistance with other protein synthesis inhibitors. 8 However, due to homology between 23S ribosomal targ -Abstract Truncated-
pharmacology & pharmacy,infectious diseases